Avantor Investor Day Presentation Deck

3. BIOPRODUCTION Recent market evolutions play to Avantor's strengths Biologics (mAbs) Viral Vector / Cell & Gene therapy ~10% of Avantor's Bioproduction revenue¹ Bioengineered (mRNA) Navantor™ MARKET TRENDS - New approvals for Cell therapy- based drugs - First Gene therapies approved 1. FY21 estimates, excluding pending M&A - Viral Vector platform for COVID vaccines AVANTOR RELEVANCE NOVEL SINGLE- USE ASSEMBLIES SMALL SCALE GMP REAGENTS INNOVATIVE, CLOSED-SYSTEM SAMPLING TECHNOLOGIES 30

View entire presentation